Abstract
Background High levels of excess mortality during periods of active influenza circulation in France were observed in the years preceding the COVID-19 pandemic. Some of the factors that affect the rates of influenza associated mortality are influenza vaccination coverage levels in different population groups and practices for testing for influenza and related use of antiviral medications for various illness episodes (including pneumonia hospitalizations) during periods of active influenza circulation in the community.
Methods Data on sentinel ILI surveillance and sentinel virological surveillance in France were combined in a framework of a previously developed regression model to estimate the number of deaths associated with the circulation of the major influenza subtypes (A/H3N2, A/H1N1, B/Yamagata and B/Victoria) in France between 2015-2019.
Results Between week 3, 2015 and week 2, 2020, there were on average 15403 (95% CI (12591,18229)) annual influenza-associated deaths, of which 60.3% (49.9%,71.9%) were associated with influenza A/H3N2, and 29.5% (13.3%,45.5%) were associated with influenza B/Yamagata. During weeks when levels of ILI consultation in mainland France were above 50 per 100,000 persons, 7.9% (6.5%,9.4%) of all deaths in France were influenza-associated.
Conclusions High rates of influenza-associated mortality in France prior to the COVID-19 pandemic suggest that boosting influenza vaccination coverage in different population groups and testing for influenza in respiratory illness episodes (including pneumonia hospitalizations) during periods of active influenza (particularly influenza A/H3N2) circulation in combination with the use of antiviral medications is needed to mitigate the impact of influenza epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study involves no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
edmigo3{at}gmail.com
Data Availability
This manuscript is based on aggregate, publicly available data that can be access through refs. 19,20, 22,23
https://www.sentiweb.fr/france/fr/?page=table
https://www.insee.fr/fr/statistiques/4931039?sommaire=4487854#tableau-figure1
